SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-220584
Filing Date
2020-08-14
Accepted
2020-08-14 17:08:44
Documents
18
Period of Report
2020-08-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d87599d8k.htm   iXBRL 8-K 36638
2 EX-1.1 d87599dex11.htm EX-1.1 188952
3 EX-5.1 d87599dex51.htm EX-5.1 7266
4 EX-5.2 d87599dex52.htm EX-5.2 7000
5 EX-10.1 d87599dex101.htm EX-10.1 67957
9 GRAPHIC g87599g35b84.jpg GRAPHIC 3910
10 GRAPHIC g87599g58k62.jpg GRAPHIC 15521
  Complete submission text file 0001193125-20-220584.txt   535046

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20200812.xsd EX-101.SCH 3085
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20200812_lab.xml EX-101.LAB 18123
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20200812_pre.xml EX-101.PRE 11415
11 EXTRACTED XBRL INSTANCE DOCUMENT d87599d8k_htm.xml XML 3350
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 201106480
SIC: 2834 Pharmaceutical Preparations